StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Manas Jaiswal

BUYEmcure Pharmaceuticals Limited

byManas JaiswalHorizon: NA (inferred Swing (≤2wk))23 Jun 2026via CNBC Awaaz.

Entry₹1,816.6Inferred
Target₹2,000
Total upside +10.10% (call closed)
Stop lossNot given
At expiry₹1,833.67 Jul 2026, 3:30 pm
Expired+0.94%
Follow Manas Jaiswal for new calls(32% target hit, 272 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 99 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 5:42 pm IST
3 supporting0 opposing
Supports the BUY call (3)

Emcure Pharmaceuticals Limited's subsidiary, Marcan Pharmaceuticals Inc., has acquired all Class E Special Shares in its step-down subsidiary, Mantra Pharma Inc., for CAD $50 million. This acquisition

NSE · Acquisition·3 Jul · 4d ago

(opens in new tab)

Emcure Pharmaceuticals Ltd announced an acquisition/investment in a step-down subsidiary by its subsidiary.

BSE · Company Update·3 Jul · 4d ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·2 Jun · 1mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.